Immune Checkpoint Inhibitors in Lung Cancer and Melanoma-Reference-Cited by-同舟云学术

Immune Checkpoint Inhibitors in Lung Cancer and Melanoma

Published:2019-10 Issue:5 Volume:35 Page:150932
ISSN:0749-2081
Container-title:Seminars in Oncology Nursing
language:en
Short-container-title:Seminars in Oncology Nursing

Author:

Madden Kathleen,Kasler Mary Kate

Publisher

Elsevier BV

Subject

Oncology (nursing)

Reference62 articles.

1. Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial;Larkin;J Clin Oncol,2018

2. Harnessing the immune system in the treatment of melanoma;McGettigan;J Adv Pract Oncol,2018

3. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

4. PS3 KEYNOTE-024 Update: pembrolizumab vs platinum-based chemotherapy for advanced NSCLC with PD-L1 tumor proportion score ≥50%;Brahmer;J Thorac Oncol,2018

5. Rubin KM. PD-1 inhibitor therapy: consensus statement from the faculty of the Melanoma Nursing Initiative on managing adverse events;McGettigan;J Adv Pract Oncol,2017

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PLOD3 facilitated T cell activation in the colorectal tumor microenvironment and liver metastasis by the TNF-α/ NF-κB pathway;Journal of Translational Medicine;2024-01-06

2. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma;Melanoma Research;2023-12-19

3. Construction and Evaluation of an M2 Macrophage-Related Prognostic Model for Colon Cancer;Applied Biochemistry and Biotechnology;2023-11-21

4. A decade of liver organoids: Advances in disease modeling;Clinical and Molecular Hepatology;2023-07-01